The company has announced that its transcatheter aortic valve system, Ken-Valve, has recently received approval from the Department of Health of the Hong Kong Special Administrative Region.

The firm is actively advancing the commercialization of this product within the Hong Kong market.

Owing to the product's distinct advantages, ongoing therapy promotion efforts, and extensive commercialization experience, Ken-Valve has already gained broad market recognition.

This latest approval from the Hong Kong Department of Health further validates the product's potential in treating aortic regurgitation, including cases with concurrent stenosis.

The company remains committed to fully accelerating the global commercialization process for Ken-Valve to further realize its long-term strategic objectives.